Cardiovascular drugs most lucrative for Hungary pharma market in 2009, generating revenues of $581.8 million

25 August 2010

Having displayed fluctuating growth rates in the years 2005-2009 the Hungary pharmaceuticals market is expected to stabilize and perform low growth rates over the years up to 2014, according to a new report from Venn Research.

The Hungary pharmaceuticals market generated total revenues of $2,706.1 million in 2009, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2005-2009. In comparison, the Polish and Czech markets grew with CAGRs of 5.8% and 10% respectively, over the same period, to reach respective values of $6,860.8 million and $2,867.5 million in 2009.

Cardiovascular sales proved the most lucrative for the Hungary pharmaceuticals market in 2009, generating total revenues of $581.8 million, and equivalent to 21.5% of the market's overall value, says Venn Research. In comparison, sales of central nervous system generated revenues of $507.3 million in 2009, equating to 18.7% of the market's aggregate revenues.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical